Journal of Reproductive Medicine Gynaecology & Obstetrics Category: Medical Type: Commentary

Recognizing the Imperative of Abortion Access in Gestational Cancer

Weinstein A1, Chafitz O1, Sheedy C2, Figueroa M1,3 and Oladipo AF1,3*

1 Department of obstetrics and gynecology, Hackensack University Medical Center, 20 Prospect Avenue, Suite 601, Hackensack, New Jersey 07601, United states
2 Department of family medicine, Rutger-Robert Wood Johnson Medical School, Freehold, NJ, United states
3 Hackensack meridian school of medicine, Nutley, NJ, United states

*Corresponding Author(s):
Oladipo AF
Department Of Obstetrics And Gynecology, Hackensack University Medical Center, 20 Prospect Avenue, Suite 601, Hackensack, New Jersey 07601, United States
Tel:+1 5519962765,
Fax:+1 2014878516

Received Date: Aug 07, 2023
Accepted Date: Aug 18, 2023
Published Date: Aug 25, 2023

Gestational cancer refers to a malignant diagnosis that is made during pregnancy, and has an estimated occurrence of 1 in 1000 pregnancies [1]. Common cancers in pregnancy include breast, cervical, ovarian, hematologic cancer and melanoma [2]. Diagnosing malignancy in pregnancy is often challenging, considering that constitutional symptoms are often misattributed to physiologic symptoms of pregnancy [2]. The management of cancer in pregnancy is complex and takes into account both maternal and fetal impact. Risks and benefits regarding chemotherapy, radiation therapy, surgery and early delivery must all be considered [3]. A multidisciplinary approach is recommended to help patients navigate through difficult decision making in gestational cancer. 

Chemotherapy is the mainstay treatment for many malignant conditions. The fetal implications of chemotherapeutic agents vary with trimester [3-5]. Exposure to chemotherapy in the first trimester significantly increases the risk for spontaneous abortion and for developing malformation in surviving pregnancies. Given the high teratogenic potential during organogenesis, most recommend avoidance of chemotherapy during the first 13 weeks of gestation [3-5]. Administration of chemotherapy during the second and third trimester is considered an acceptable approach, with the most common fetal risks including fetal growth restriction, preterm prelabor rupture of membranes, preterm contractions and preterm delivery [6]. Long term implications of antenatal chemotherapy in the second and third trimester are not well elucidated, though existing data has reassuringly not demonstrated significant neurodevelopmental impact [7]. Pelvic radiation therapy unavoidably results in intrauterine fetal demise and decreases the likelihood of future fertility, whereas non-pelvic radiation therapy has promising pregnancy outcomes [6]. When treatment for gestational cancer requires surgery, the optimal timing of surgical intervention is early in the second trimester, when the risk for pregnancy loss is low and the uterine size does not yet compromise intraabdominal access [6,8-11]. A minimally invasive approach is preferred over an open laparotomy, though is not without risk. While laparoscopy allows for shorter operating times and fewer adverse fetal effects, risks of laparoscopy during pregnancy include uterine perforation, hypercapnia and uterine hypoperfusion [6,12]. 

Given the complexity of pregnancy complicated by an oncologic diagnosis, multidisciplinary models have been proposed to help facilitate care amongst different subspecialists. While national guidelines have proposed termination of pregnancy as an option in the individualized care of gestational cancer patients, the involvement of family planning specialists has not been standardized [6]. In fact, there is a paucity of published data regarding termination of pregnancy in the setting of gestational cancer. 

We recently published a manuscript detailing the diagnosis and management of a high risk Gastrointestinal Stromal Tumor (GIST) in a pregnant patient at our institution, who presented with an abdominal mass in the first trimester [13]. Surgical excision confirmed stage IIIb small intestinal GIST, and genetic testing of the tumor indicated benefit from adjuvant chemotherapy with Imatinib. Forgoing treatment placed the patient’s probability of two year recurrence free survival at 1%. “The timing of our patient's diagnosis contributed to the complexity of its management: the benefit of Imatinib in a patient with a high risk for tumor recurrence had to be weighed against the risk of Imatinib initiation in the first trimester of a desired pregnancy” [13]. The comprehensive care team included providers from maternal fetal medicine, gynecologic oncology, surgical oncology, and complex family planning. The collaborating subspecialists were able to offer truly comprehensive options counseling, and the patient ultimately elected to undergo a dilation and evacuation at 19 weeks gestation. Our experience with a pregnancy complicated by high grade disease highlighted the importance of providing gestational cancer patients with abortion access. 

The recent overturn of federal protections on abortion access has impacted reproductive rights in the United States [14-16]. Many states have adopted restrictions on termination of pregnancy care, increasing the access to abortion gap across the country [17]. The political climate change has affected the autonomy of millions, including those afflicted by gestational cancer [18]. The hindrance of necessary medical care to this patient cohort is discongruent with national medical guidelines. Many Americans now have to decide between optimizing their prognosis at the expense of teratogenic effects of chemoradiation therapy and delaying their necessary treatment so as to avoid fetal complications. Traveling to states with more liberal abortion policies is a marginalizing option, as it disproportionately excludes those without the financial means to afford travel expenses. With fewer locations offering termination of pregnancy, providers are overwhelmed by increasing patient load, resulting in longer wait times for procedure completion; this in turn poses undo risk related to terminations performed at later gestational ages. 

While inequitable access to health care precludes optimal standardization of care in gestational cancer, efforts should be channeled towards integrating complex family planning into multidisciplinary care teams. Offering termination of pregnancy as a part of the plan of care discussion empowers gestational cancer patients to make a truly informed decision.


  1. Korenaga TK, Tewari KS (2020) Gynecologic cancer in pregnancy. Gynecol Oncol 157: 799-809.
  2. Hepner A, Negrini D, Hase EA, Exman P, Testa L, et al. (2019) Cancer During Pregnancy: The Oncologist Overview. World J Oncol 10: 28-34.
  3. Kalampokas E, Vlahos N, Kalampokas T, Gurumurthy M (2021) Common Malignancies During Pregnancy: A Comprehensive Review. Cancer Diagn Progn 1: 103-109.
  4. Van Calsteren K, Verbesselt R, Ottevanger N, Halaska M, Heyns L, et al. (2010) Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand 8: 1338-1345.
  5. Esposito S, Tenconi R, Preti V, Groppali E, Principi N (2016) Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes. Medicine (Baltimore) 95: 4899.
  6. Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, et al. (2019) Gynecologic cancers in pregnancy: Guidelines based on a third international consensus meeting. Ann Oncol 30: 1601-1612.
  7. Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, et al. (2012) Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol 13: 256-264.
  8. Streffer C, Shore R, Konermann G, Meadows A, Uma Devi P, et al. (2003) Biological effects after prenatal irradiation (embryo and fetus). A report of the International Commission on Radiological Protection. Ann ICRP 33: 5-206.
  9. International Commission on Radiological Protection (2000) Pregnancy and medical radiation. Ann ICRP 30: iii-viii.
  10. Kal HB, Struikmans H (2005) Radiotherapy during pregnancy: Fact and fiction. Lancet Oncol 6: 328-333.
  11. Vandenbroucke T, Verheecke M, Fumagalli M, Lok C, Amant F (2017) Effects of cancer treatment during pregnancy on fetal and child development. Lancet Child Adolesc Health 1: 302-310.
  12. Shigemi D, Aso S, Matsui H, Fushimi K, Yasunaga H (2019) Safety of Laparoscopic Surgery for Benign Diseases during Pregnancy: A Nationwide Retrospective Cohort Study. J Minim Invasive Gynecol 26: 501-506.
  13. Sheedy CM, Weinstein A, Chafitz O, Oladipo AF (2023) Diagnosis and management of high risk gastrointestinal stromal tumor in first trimester pregnancy: A case report and review of the literature. Heliyon 9: 15858.
  15. JUSTIA (1973) Roe v. Wade, 410 U.S. 113 (1973). JUSTIA, Mountain View, California, USA.
  16. JUSTIA (1992) Planned Parenthood of Southeastern Pa. v. Casey, 505 U.S. 833 (1992). JUSTIA, Mountain View, California, USA.
  17. Center for Reproductive Rights (2022) After Roe fell: abortion laws by state. Center for Reproductive Rights, New York, USA.
  18. Silverstein J, Van Loon K (2022) The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers. JAMA Oncol 8: 1394-1395.

Citation: Weinstein A, Chafitz O, Sheedy C, Figueroa M, Oladipo AF (2023) Recognizing the Imperative of Abortion Access in Gestational Cancer. J Reprod Med Gynecol Obstet 8: 146.

Copyright: © 2023  Weinstein A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Herald Scholarly Open Access is a leading, internationally publishing house in the fields of Sciences. Our mission is to provide an access to knowledge globally.

© 2024, Copyrights Herald Scholarly Open Access. All Rights Reserved!